Immunotherapy: Open Access
Open Access
ISSN: 2471-9552
ISSN: 2471-9552
College of Life Sciences, Shihezi University, Xinjiang, China
Commentary
Attention should be paid to the Adverse Reactions of PD-1/PD-L 1 Inhibitors
Author(s): Peng Wu*, Shulan Lin, Jiao Jiao and Chunyi Li
The adverse reactions caused by using programmed cell death-1/programmed cell death ligand-1(PD-1/PD-L1)
inhibitors were evaluated. PD-1 is an immune checkpoint receptor which expresses and activates specific immune
cells. When PD-1 binds to immune cells, it will make them useless against cancer cells. PD-1/PD-L1 inhibitor has
been an emerging therapy recently and is widely used in cancer patients. PD-1/PD-L1 inhibitor may cause immune
imbalance in common cancer patients and organ transplant cancer patients, which may lead to T cells attacking their
own organs, causing some adverse reactions against patients, and even endangering their lives... View More»